Reports
U.S. Diabetes Devices Market Size, Growth Report, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
U.S. Diabetes Devices Market Overview
The U.S. diabetes devices market was valued at 28.57 billion in 2025. The market is projected to account for a CAGR of 6.5% between 2026 and 2034. The rising prevalence of diabetes and pre-diabetes among U.S. adults is driving increased need for diabetes devices in the country.
Market Statistics
Ket Takeaways
- The continuous glucose monitoring devices segment led with a 37.0% revenue share in 2025. This is due to the rising cases of diabetes in the U.S.
- The hospitals segment accounted for a 45.0% market share in 2025. The increased burden of diabetes has resulted in high adoption of advanced diabetes technologies across hospitals.
- The homecare segment is projected to grow at a 5.6% CAGR. This is owing to the rapid adoption of smart and minimally invasive devices.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Growing awareness among U.S. citizens about diabetes has resulted in increased adoption of diabetes devices.
- The rising economic burden of diabetes has led to an increased need for diabetes management.
- The increased focus on the integration of insulin pumps with automated insulin delivery systems is expected to create several market opportunities.
- The high cost of advanced technologies may present market challenges.
AI Impact on U.S. Diabetes Devices Market
- AI is useful in monitoring blood sugar levels in real time and providing straightforward interpretation to improve control.
- AI is also effective in enhancing insulin devices by modifying doses according to real-time glucose levels.
- AI facilitates remote monitoring, making diabetes management possible from anywhere.
- It aids in identifying risk factors through health data patterns.
What are Diabetes Devices?
Diabetes devices encompass a wide range of products and services related to the management and treatment of diabetes within the United States. This market includes devices such as glucose monitoring systems, insulin delivery systems, continuous glucose monitoring (CGM) devices, insulin pumps, insulin pens, and other related accessories and consumables.
To Understand More About this Research: Download Sample Report
These include blood glucose meters and testing strips used by individuals with diabetes to monitor their blood sugar levels. The market for glucose monitoring systems includes both traditional glucose meters and newer technologies such as continuous glucose monitoring (CGM) systems.
CGM devices continuously monitor glucose levels throughout the day and night, providing real-time data to users. These devices typically consist of a small sensor placed under the skin, a transmitter, and a receiver or smartphone app for displaying glucose readings. The CGM market has been experiencing significant growth due to the benefits of continuous glucose monitoring in diabetes management.
Furthermore, rising FDA approvals, awareness among U.S. citizens, the aging population, sedentary lifestyles, and innovations in minimally invasive procedures to manage real-time glucose levels are key enablers in the adoption of diabetes devices. Further, obesity and a busier lifestyle also cause diabetes. Moreover, the high prevalence of the obese population in the U.S. will spur the demand for diabetes devices for diagnosis and prevention.
For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), approximately 35% of adults in the U.S. have obesity.
Texas expected to grow at the rapid rate. This growth is primarily due expected rise in diabetics in coming years. As per the estimates of the Texas Diabetes Council (TDC), in 2021, diabetes prevalence rate stood at 11.5%, constituting 2.5 Mn people in the state. Rise in prevalence rate is primarily due to late diagnosis, owing to delay in treatment, risk of diabetes-based complications, such as heart attacks, renal failures, diabetic keto-acidosis, and stroke.
Moreover, the high consumption of fast food across the U.S. has increased the risk of obesity and type 2 diabetes. For instance, in the U.S. more than 25% of adults in the U.S. consume fast food daily. The market is influenced by factors such as the prevalence of diabetes, technological advancements in device design and functionality, regulatory landscape, reimbursement policies, and consumer preferences. With the rising prevalence of diabetes and increasing awareness about the importance of diabetes management, the market for diabetes devices continues to grow, presenting opportunities for innovation and market expansion.
Growth Factors
Rising Prevalence of Pre-Diabetic and Diabetic Among U.S Adults
Rising diabetes and pre-diabetes are the conditions in which blood glucose levels are recorded above their optimum range. High glucose levels cause many health ailments and damage prime organs, such as heart, nerve-related disorders, eye complications, and kidneys among geriatrics. As per the estimates of the NIDDKD, in 2021, there were around 38.4 Mn people aged 18 years and above in the U.S. living with diabetes, constituting 11.6% of the country’s population. Of these, only 29.7 million people have been diagnosed. It also includes 3,52,000 children and adults aged below 20 years, with 304,000 with type I diabetes.
Moreover, the diagnosed diabetes prevalence rate in was seen highest among Indian-born Americans & Alaska native adults (13.6%), followed by non-Hispanic (12.1%), Hispanics (11.7%), and non-Hispanic whites (6.9%)
The Rising Economic Burden of Diabetes Increases the Need for Diabetes Management
The rising economic burden of diabetes necessitated the need to manage it at the individual level. In 2022, it is estimated that the total cost of diabetes in the U.S. stood at USD 412.9 Bn, which includes USD 306.6 Bn and USD 106.3 Bn in direct and indirect medical costs to manage blood glucose. Diabetics, on average, spend around USD 19,736 annually, of which nearly USD 12,022 is directly attributed to diabetes complications.
Diabetes supplies and glucose-lowering agents account for almost 17% of total costs attributed to diabetes. Indirect costs include reduced employment due to disability (USD 28.3 Bn), medication-related presenteeism (USD 35.8 Bn), and lost productivity owing to premature deaths (USD 32.4 Bn).
Restraining Factors
Stringent Regulations for Approval of Diabetes Devices may Hamper the Market Growth
There are certain regulations imposed for the commercialization of medical devices, including those for use in diabetes management. This is attributed to eliminating risks associated with a device. For instance, technologies such as reusable and more accurate devices are still in the early stages of development. These devices must be accurate and suitable for all age groups and patients. However, certain regulatory approval processes are required to commercialize diabetes devices.
Report Segmentation
The market is primarily segmented based on type, end-use, and distribution channel.
| By Type | By End-use | By Distribution Channel |
|
|
|
To Understand the Scope of this Report:Request Customization
By Type Insights
The Continuous Glucose Monitoring Devices Segment Held the Largest Market Share in 2025
Continuous glucose monitoring devices segment accounted for the largest market share valued at 37.0% in 2025. This dominance is primarily due to rise in rise diabetics in the U.S. with rising cases of people suffering with obesity and faulty lifestyle. Moreover, rising awareness among the citizens increasing the adoption of wearables counting calories and helping in maintaining blood glucose level on real time basis.
| Device Type | Description | Function | Common Usage |
| BGM Devices (Blood Glucose Meter) | Small machines for measuring glucose manually | Produce one result each time testing is done | Test blood glucose at home every day |
| Continuous Glucose Monitoring (CGM) Devices | Blood glucose monitoring devices that measure glucose continuously in real time | Glucose measurement in real time | Continuous monitoring |
| Insulin Devices | Insulin delivery devices such as insulin pens and insulin pumps | Inject insulin into the body | Diabetes management |
By End-Use Insights
The Hospitals Segment Held the Largest Revenue Share in 2025
The hospitals segment held the largest market share accounting for 45.0% in 2025. The segment’s growth is attributed to factors such as rising cases of diabetes and adopting advanced diabetes technologies and devices to improve patient care. The rapid increase in the burden of diabetes has led to the improvement of the capacity of primary health care for early diagnosis, treatment, as well as prevention of diabetes-related complications.
For instance, according to the statistics reported by the U.S. Department of Commerce, over 10% of the population in the U.S. are diagnosed with Type 1, Type 2, or gestational diabetes.
| End-Use | Simplified Description | What It Does | Common Use |
| Hospitals | Medical institutions that treat patients | Used to monitor and manage diabetes | For monitoring and managing critically ill or admitted patients |
| Diagnostic Centres | Laboratories that conduct diagnostic tests | Used to test and analyze glucose levels | Conducts glucose level testing and analysis |
| Homecare | Home settings where patients monitor themselves | Useful for self-monitoring and managing diabetes | Used in monitoring and managing diabetes |
Key Market Players & Competitive Insights
Strategic Partnerships to Drive the Competition
The U.S. diabetes devices market is highly competitive with presence of both big and smaller players. Companies in the sectors are seeking heavy investments to increase their technological abilities to manage diabetes effectively. For instance, in January 2024, Adipo Therapeutics, a pharmaceutical company involved in the development of obesity & type II diabetes in collaboration with Purdue University, have secured funding USD 1.9 Mn. This funding will used in development of promising candidate “ADPO-002” to treat obesity-borne diabetic population.
Some of the major players operating in the global market include:
- Abbott Diabetes Care
- B Braun Melsungen AG
- BD
- Biocorp
- Johnson & Johnson
- LifeScan Inc.
- Medtronic PLC
- Molex
- Roche Diabetes Care
- Senseonics, Inc.
- Tandem Diabetes Care, Inc.
Recent Developments in the Industry
- March 2026: Novo Nordisk received the U.S. FDA approval for Awiqli as the first and only once-weekly basal insulin for adults with type 2 diabetes. The company stated that the approval will help reduce the injection burden from 365 to 52 doses per year. (Source: prnewswire.com)
- March 2026: Afon Technology announced that its Glucowear device achieved approximately 75% accuracy in distinguishing between normal and high glucose levels in initial real-world trials. (Source: afontechnology.com)
- December 2024: Dexcom introduced a Generative AI platform on Google Cloud’s Vertex AI and Gemini models. The system analyzes glucose trends, activity, and sleep patterns to deliver personalized nudges, promoting real-time lifestyle changes. (Source: dexcom.com)
Future Outlook
The U.S. market for diabetes devices will continue to grow steadily owing to the increasing prevalence of diabetes as well as growing popularity of CGM wearable technology. Artificial Intelligence and analytics, alongside the introduction of remote monitoring technology, will pave the way for new innovations. There will be additional improvements in minimally invasive devices and smart technology.
Report Coverage
The diabetes devices market report emphasizes on key countries across the country to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, type, end-use, distribution channel, and their futuristic growth opportunities.
U.S. Diabetes Devices Market Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 28.57 billion |
| Market size value in 2026 | USD 30.41 billion |
| Revenue forecast in 2034 | USD 50.39 billion |
| CAGR | 6.5% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Segments covered |
|
| Competitive Landscape |
Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments |
| Report Format | PDF + Excel |
| Customization | Report customization as per your requirements with respect to countries, country, and segmentation. |
FAQ's
The key companies in U.S. Diabetes Devices Market Abbott Diabetes Care, BD, Medtronic PLC, Molex, Roche Diabetes Care.
U.S. Diabetes Devices Market exhibiting the CAGR of 6.5% during the forecast period.
U.S. Diabetes Devices Market report covering key segments are type, end-use, distribution channel
The key driving factors in U.S. Diabetes Devices Market Rising prevalence of pre-diabetic and diabetic among U.S adults
U.S. Diabetes Devices Market Size Worth $ 50.39 Billion By 2034.
Download Sample Report of U.S. Diabetes Devices Market Size, Growth Report, 2026-2034
Please fill out the form to request a customized copy of the research report.
